Epistemonikos: Database of the best Evidence-Based Health Care

2 articles (2 References) loading

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the Cross Trial Safety Analysis

Authors » Solomon SD , Wittes J , Finn PV , Fowler R , Viner J , Bertagnolli MM , Arber N , Levin B , Meinert CL , Martin B , Pater JL , Goss PE , Lance P , Obara S , Chew EY , Kim J , Arndt G , Hawk E , Cross Trial Safety Assessment Group

Journal » Database of Abstracts of Reviews of Effects (DARE)

Year » 2011

Links » Database of Abstracts of Reviews of Effects (DARE)

This article includes 1 Systematic review Systematic reviews (1 reference)

Loading references information

CRD SUMMARY: This review concluded that the risk of experiencing a cardiovascular event was greater with higher doses of celecoxib and with a greater underlying risk of such events. Despite some limitations in the review, the conclusion seems reliable for the populations evaluated in the trials, but might not be generalisable to populations treated with celecoxib on a long-term basis.

Review: celecoxib increases risk for cardiovascular events; risks are greatest with higher doses.

Authors » Rothschild B

Journal » ACP journal club

Year » 2008

Links » Pubmed

This article includes 1 Systematic review Systematic reviews (1 reference)

Loading references information

CRD SUMMARY:

This review concluded that the risk of experiencing a cardiovascular event was greater with higher doses of celecoxib and with a greater underlying risk of such events. Despite some limitations in the review, the conclusion seems reliable for the populations evaluated in the trials, but might not be generalisable to populations treated with celecoxib on a long-term basis.

Structured summary of this review

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the Cross Trial Safety Analysis

Review: celecoxib increases risk for cardiovascular events; risks are greatest with higher doses.

CRD SUMMARY: